Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G antigen 12G (GAGE12G)
- Target
- GAGE12G
- Molecular classification
- Cancer/testis antigen (CT antigen), Protein coding gene
01
Overview
G antigen 12G (GAGE12G) is a member of the cancer/testis antigen family, encoding a protein predominantly expressed in germ cells and aberrantly in various cancers. Like other GAGE proteins, GAGE12G is implicated in promoting cancer cell survival, apoptotic resistance, and possibly contributing to metastasis. Cancer/testis antigens are prime candidates for cancer immunotherapy due to their restricted expression, serving as biomarkers and therapeutic targets. No drugs specifically target GAGE12G yet, but cytotoxic agents and immune therapies may act on the family more broadly. Expression of GAGE12G and related antigens can predict resistance to DNA-damaging agents and poor clinical prognosis in certain cancers.
- Other names
- GAGE12GGAGE-12GOTTHUMG00000024148AL4CT4.7G antigen 12F/G/IG antigen 12Icancer/testis antigen 4.7
02
Mechanism of action
For general CT antigen targets: enhancement of cancer cell survival, resistance to apoptosis, and evasion of cytotoxic drugs. Possible immunotherapeutic targeting due to cell surface or restricted antigenic profile.
03
Biological functions
Cell survivalApoptotic resistanceCell proliferationPotential role in cell migration and invasion (by analogy to GAGE family members)
04
Disease associations
Cancer (oncogenesis, metastasis)
05
Safety considerations
Predominant expression in immune-privileged tissues (testis) and cancer generally reduces risk of autoimmune toxicity, but off-target effects must be considered in immunotherapy
06
Interacting drugs
Cytotoxic agents (etoposide, paclitaxel)
07
Biomarkers
Expression of GAGE proteins (including GAGE12G) may serve as a prognostic and predictive marker in cancerMay have a role in patient selection for immunotherapy targeting CT antigens
Beyond the preview
Go deeper on G antigen 12G (GAGE12G).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G antigen 12G (GAGE12G).